Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

TPG Buys Par Pharmaceuticals for $1.9B, Spiking PRX Stock

Par Pharmaceuticals PurchasePar Pharmaceuticals (PRX) of Woodcliff Lake, N.J., announced early Monday that that it has agreed to be purchased by private investment firm TPG for $1.9 billion, or $50 per share, which as listed as a 37 percent premium on PRX stock at Friday’s close. With the news, Par’s stock jumped more than 35 percent to be right at the purchase price of $50 per share after hovering around $37 per share for a month.

Par is allowed to consider other proposals until late August before this deal can be finalized. But it is expected to be consummated before the end of the calendar year.

In announcing the agreement, Par CEO Patrick G. LePore said, “We are excited about this transaction as it delivers compelling value to our shareholders. While my focus and that of the Par Board of Directors was on shareholder value, we are very pleased that Par will be acquired by TPG, a leading global private investment firm whose substantial resources and healthcare experience will enable Par to continue to invest in its future long-term growth.”

“We are excited for the opportunity to invest in Par, a leading generic pharmaceutical company that has a long track record of success via its focus on complex products and its strong, diversified product pipeline,” said Todd B. Sisitsky, partner at TPG.  “The company is positioned to benefit from the strong macro trends of a greater focus on cost effective healthcare solutions and the increasing demands from an aging population.  We look forward to partnering with this talented management team to continue developing an attractive platform for expansion.”

The agreement means that a Par stockholder will receive $50 cash from TPG for each share of stock it owns. Only a better proposal in the next month will scuttle this deal.

Hedge funds who have had a stake in PRX have just seen a quick 40-percent return on money in one trading day. For instance, at the end of March, Ralph Whitworth’s Relational Investors had committed nearly $137 million in PRX, while Jacob Gottlieb’s Visium Asset Management was in for $24 million.  PRX was trading at about $40 per share at the end of March.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.